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Introduction 
Obesity is a global epidemic, and its prevalence has nearly tripled between 1975 and 2016. Obesity is 
also associated with higher risk of type 2 diabetes mellitus, dyslipidemia, arterial hypertension and 
CKD [1–3]. In end-stage renal disease (ESRD), large epidemiologic studies reported a U-shaped 
association between body mass index (BMI) and death [4, 5]. Although proposed mechanisms for 
this “obesity paradox” [5] in hemodialysis patients include comorbidities and malnutrition, 
identification of biochemical mediators, possibly associated with adverse outcomes, is needed in 
dialysis patients.  
Vitamin K is a fat-soluble vitamin existing in two biologically active forms: vitamin K1 or 
phylloquinone and vitamin K2 or menaquinone, which includes 12 different menaquinones (from 
MK2 to MK11) [6], the most studied of which are MK4 and menaquinone-7 (MK7) [7, 8]. Vitamin K 
acts as the coenzyme of a carboxylase that determines carboxylation of glutamic acid residues, 
resulting in the formation of the amino acid g-carboxy-glutamic acid (Gla). In the liver, this reaction 
controls the production of vitamin K-dependent proteins (VKDPs), such as coagulation factors, and in 
extrahepatic tissues the VKDPs, bone and matrix Gla proteins (BGP and MGP, respectively) [7,8]. BGP 
is a small protein produced by osteoblasts under the control of vitamin D. It contains three GLA  
residues that enable its binding to hydroxyapatite in bone [9].  
BGP knockout mice develop hyperostosis, showing that it has a role in promoting normal bone 
mineralization [10].Vitamin K deficiency in bone can be measured indirectly by measuring 
undercarboxylated BGP (ucBGP). MGP is a potent inhibitor of vascular calcification (VC), and it is 
produced by osteoclasts, chondrocytes and vascular smooth muscle cells (VSMCs) [11]. MGP 
knockout mice experience pathological fractures due to severe osteoporosis and widespread VC 
[12].  
In a secondary analysis of the VIKI study, we evaluated the relationship between vitamin K levels and 
BMI value in hemodialysis patients according to the hypothesis that the impact of BMI on mortality 
is in part driven by low vitamin K levels (Figure 1). 
 
Materials and methods  
This study is a secondary analysis of the VIKI study, involving 18 dialysis centers in Italy [13]. Ethics 
committees were approved for the study (approval dates ranged from July 14, 2008 to October 26, 
2009), in accordance with the regulations in place related to observational studies. Patient 
enrollment took place between November 2008 and November 2009, and follow-up to assess vital 
status was performed in December 2011. We included adult patients of both genders who had been 
on hemodialysis for >1 year, provided that they gave their informed consent, in writing, for the use 
of their medical records for the study. We excluded patients who had a life expectancy <6 months, 
cancer (with the exception of basal cell carcinoma), coagulation disorders or conditions that, 
according to the investigator, could interfere with the study outcome. We collected the following 
information: demographic data (initials or ID number, gender, age); renal failure history (cause, type 
of hemodialysis, duration of hemodialysis in months, transplantation history); lifestyle (smoking 
status, alcohol consumption) and medical history. BMI was classified into the following categories: 
underweight (BMI < 18.5 kg/m2), normal weight (18.5 ≤ BMI < 25 kg/m2), overweight (25 ≤ BMI < 30 
kg/m2) and obese (BMI ≥ 30 kg/m2). 
 
Laboratory determination 
Parathyroid hormone (PTH) 
The method for quantitative determination of PTH in serum was the automated LIAISON® N-Tact® 
PTH Assay 310910 (DiaSorin Inc., Stillwater, MN, USA), a direct, two-site, sandwich-type 
chemiluminescence immunoassay (CLIA) carried out on the LIAISON® (DiaSorin Inc., Stillwater, MN, 
USA) instrument. The analytical sensitivity was 1 pg/mL and the intra-assay and inter-assay 
coefficients of variation (CVs) were 3.7–6.3 and 3.5%–5.3%, respectively. 
25-OH vitamin D 
For quantitative determination of total 25-OH vitamin D (both D2 and D3 form) in serum, we used 
the automated LIAISON® 25 OH Vitamin D TOTAL Assay 310600, a direct competitive CLIA executed 
on the LIAISON (DiaSorin Inc., Stillwater, MN, USA) instrument. The analytical sensitivity was <10 
nmol/L, and the intra-assay CV was between 2.9% and 5.5%, while the inter-assay CV was 6.3%–
12.9%.  
Total BGP 
The method for the quantitative determination of total BGP in serum was the automated LIAISON® 
Osteocalcin Assay 310950 (DiaSorin Inc., Stillwater, MN, USA), a direct, two-site, sandwich-type CLIA 
executed on the LIAISON® (DiaSorin Inc., Stillwater, MN, USA) instrument. The analytical sensitivity 
was <0.3 ng/mL and the intra-assay CV was 3%–8%, while the inter-assay CV was 4%–9%. 
Undercarboxylated BGP (ucBGP) 
For quantitative determination of the ucBGP, we used the Glu-osteocalcin Enzyme Immuno Assay 
(EIA) Kit MK118 (Takara Bio Inc., Otsu, Shiga, Japan), a manual solidphase EIA based on a sandwich 
method that utilizes two mouse monoclonal anti-ucBGP antibodies to detect ucBGP by a two-step 
procedure. One of the mouse monoclonal anti-ucBGPs is immobilized onto the micro-titer plate and 
blocked against non-specific binding. Samples are added to each well and incubated. The second 
step is to wash the plate and to add the second anti-BGP labeled with per-oxidase (POD). The 
reaction between POD and substrate (H2O2 and 3,3′, 5,5′ tetramethyl-benzidine) results in color 
development with intensities proportional to the amount of ucBGP present. The analytical sensitivity 
was 0.25 ng/mL and the intra-assay and inter-assay CVs were 4.4–6.7 and 5.7%–9.9%, respectively. 
Total matrix GLA protein (MGP) 
The quantitative determination of MGP was performed using the Human MGP-Matrix Gla Protein Kit 
(Biomedica Medizinprodukte GmbH & Co KG, Wien, Austria). It is a manual competitive ELISA 
method designed to detectMGP in serum. The analytical sensitivity was 0.3 nmol/L, and the intra-
assay and inter-assay CVs were 5%–6% and 7%–9%, respectively. 
Undercarboxylated MGP (ucMGP) 
The measurement of the total ucMGP was performed by VitaK using a competitive ELISA, as 
described previously [14]. The analytical sensitivity was 21 nmol/L, and the intra-assay and inter-
assay CVs have been found to be 8.9% and 11.4%, respectively.  
We also measured vitamin K components (see Appendix). 
Statistics 
Data are summarized as mean ± standard deviation (SD) for normally distributed variables or as 
median and interquartile range (IQ) for non-normally distributed variables, and percentages for all 
categorical variables. The normal distribution of continuous variables was tested by the Shapiro-Wilk 
test. Categorical variables across BMI groups were analyzed by the chi-squared (χ2) test or Fisher’s 
exact method. Continuous variables among more than two groups were compared by the one-way 
ANOVA or the Kruskall-Wallis tests, as appropriate. To assess the independent correlates of BGP and 
MK7/triglycerides (dependent variables), multiple linear regression models were built up by 
including all variables which resulted to be associated with the outcome variables with a p < 0.10 at 
univariate analysis. All statistical analyses were performed using statistical SPSS 15.0 package. A 
value of p < 0.05 was considered statistically significant. 
Results 
Baseline characteristics of patients classified on the basis of BMI categories are presented in Table 1. 
45.72% were overweight or obese, 4.39% were underweight and 50.39% had normal weight. A high 
prevalence of underweight women (82% in the group with BMI less than 18.5 kg/m2) was observed. 
Obese and overweight patients had higher prevalence of diabetes and shorter dialysis vintage than 
patients who were underweight or with normal weight. 
Higher triglycerides and lower HDL levels were observed in obese and overweight patients; these 
patients received statins (41.7%), oral antidiabetic drugs (4%) and insulin (21.7%). There were no 
between-group differences in medications aimed at correcting MBD-CKD, namely calcium carbonate, 
sevelamer, lanthanum, calcitriol, vitamin D analogs and calciomimetics (Table 2). 
On univariate analyses, total and ucBGP levels were inversely related to BMI (Figure 2). By contrast, 
no association was found between this metric and total MGP and ucMGP (Table 1). Obese patients 
had higher K1 and K1/ triglycerides levels as compared to underweight patients. Furthermore, obese 
patients had lower MK7/triglycerides levels than normal weight patients (Figure 3 and Table 3). 
Multiple regression analysis adjusted for a series of potential confounders showed that BMI was 
independently related to MK7/triglycerides levels (β = −0.159; p = 0.003) (Table 4) and this was also 
when the same analysis was carried out according to BGP (β = −0.119; p = 0.012) (Table 5). 
Discussion 
We found that obese hemodialysis patients had lower MK7 levels as compared to non-obese 
patients. These are the first data to demonstrate an inverse relationship between MK7 (Vitamin K2) 
and BMI in hemodialysis patients. Furthermore, in our study, total BGP concentrations have been 
shown to be reduced in patients with greater BMI. Vitamin K deficiency and obesity are both risk 
factors for cardiovascular diseases in CKD patients. MK7 is the most widely known menaquinone. It 
is present in fermented and some animal-derived foods, and it has greater bioavailability than other 
forms of vitamin K. MK7 is used as a dietary supplement secondary to its beneficial role in human 
health [15]. A prospective population-based study of 4807 subjects without clinical history of 
myocardial infarction, followed for 7 years, showed indeed that intake of menaquinone resulted in a 
significant risk reduction in coronary heart disease, all-cause mortality and severe aortic calcification 
[16]. 
Obesity prevalence has been reported in 30% of the US dialysis population, and it was found 
associated with increased risk for adverse outcomes, death and worsening of CKD [3, 14, 17–19]; it is 
also associated with earlier and progressive bone disorders, such as osteoporosis and fractures [19]. 
In hemodialysis patients, we previously reported higher prevalence of vitamin K deficiency (up to 
35%) as compared to the general population [20–22]. In particular, lower MK7 levels was an 
independent predictor of iliac artery calcifications (OR 1.64), whereas MK4 deficiency was associated 
as predictors for aortic calcification. These findings support the role of vitamin K as an inhibitor of VC 
in the vessel wall [13, 23]. Indeed, the active MGP form (phosphorylated carboxylated: p-cMGP) 
proved to be effective in solubilizing circulating calcium crystals binding to a circulating fetuin-A 
complex. Moreover, p-cMGP has been demonstrated to inhibit the pro-osteoblastic transcription 
factor BMP-2 able to induce apoptosis and trans-differentiation of VSMCs into osteoblast-like cells 
[24]. BGP can exert a protective role on VCs through intriguing mechanism where BGP increases 
adiponectin secretion. The latter is an anti-inflammatory protein secreted by adipocytes and in the 
arterial wall, prevents the transdifferentiation of VSMCs into osteoblast-like cells in arterial media 
[25–27], thus protecting from VC development.  
In the MINOS study (774 men in osteoporosis), low total BGP levels have been shown to be a 
predictor of cardiovascular mortality, whereas higher total BGP concentrations are associated with 
lower abdominal aortic calcification progression rate and lower 10-year all-cause mortality (MINOS) 
[27].  
In conclusion, we found an association between decreased vitamin K2 and obesity. Interventional 
studies with vitamin K supplementation in obese CKD subjects are warranted to confirm the 
potential role of low levels of vitamin K as a modifiable risk factor for the high morbidity and 
mortality in obese CKD patients.  
 
Appendix 
Laboratory determination 
The Laboratory in Perugia determined vitamin K components by a simple, sensitive and selective 
reversed-phase high-performance liquid chromatography (HPLC) method, developed for the 
simultaneous determination of vitamin K in human plasma. Clear and well-separated 
chromatographic PK and MK profiles were obtained in healthy human and uremic plasma [13]. 
The adjustment for triglycerides concentration is particularly relevant for the assessment of vitamin 
K status. Vitamin K components are all liposoluble compounds that become part of chylomicrons 
after absorption from the gut and as such are transported to the liver. Vitamin K1 remains partly in 
the liver, whereas vitamin K2 is transferred to VLDL and LDL for transport and there is a close 
correlation (r = 0.99) between triglycerides concentrations and vitamin K1 [13]. Uremic plasma is 
characterized by an increased level of plasma lipids and lipoproteins, which are interfering factors to 
chromatography. Thus, we adopted a liquid-liquid extraction and then a solid-phase extraction of 
human plasma using polymeric reversed-phase cartridges, achieving good reproducibility. The 
vitamers were measured by an electrochemical detector after postcolumn reduction with platinum 
on alumina powder and using the MK8 form as the internal standard. Quantitative recovery was 
obtained in the range of 80%–96% for PK and MK vitamers. Vitamin K values were corrected 
according to triglycerides levels [13]. 
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Figure Legend 
Figure 1: Interconnection between obesity and vitamin K levels (*Schurgers et al. [11]). 
Figure 2: Total BGP levels by BMI. 
Figure 3: MK7/triglycerides levels in obese and normal weight patients. 
 
  
Table 1. Main characteristics of the patients. 
 
 
  
Table 2. Therapy by BMI. 
 
 
Table 3: Vitamin K status in patients 
 
 
 
  
Table 4: Linear regression model with outcome MK7/triglycerides (log-transformed) adjusted for 
BMI (log-transformed), HDL cholesterol (log-transformed), dialysis vintage (log-transformed), age, 
gender, MK4 (log-transformed) and decarboxylated MGP (log-transformed). 
 
 
 
Table 5: Linear regression model with outcome total BGP (log-transformed) adjusted for BMI (log-
transformed), age, gender, dialysis vintage (log-transformed), alkaline phosphatase (log-
transformed), peripheral vascular disease and DM. 
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